Gilead and Arcus believe their ‘Fc silent’ TIGIT inhibitor candidate could be best in class, but analysts think only outstanding results in lung cancer will sway investor sentiment.

Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.

Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.

The frontrunner in the new protein degrader class has shown lackluster Phase II results in breast cancer, but Arvinas hopes for success in less heavily pre-treated patients in Phase III.

Blenrep’s withdrawal will add to GSK’s blockbuster drought, and hopes of separate trial success for the BCMA-targeting drug in earlier stage myeloma may now be harder to achieve.

Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.